Company Overview and News

BidEnergy signs a deal with international logistics company

BidEnergy (ASX:BID) has signed a subscription agreement to provide its cloud‐based platform to one of the largest transportation and logistics companies operating in the Asia Pacific region.
Upvote Downvote

BidEnergy wins energy-tracking contract with retail giant in the U.S.

BidEnergy (ASX:BID) has secured a contract with one of the world’s largest retailers to provide energy-efficiency rebate tracking and administration for its U.S. locations.
Upvote Downvote

BidEnergy Ltd acquires U.S. energy rebate capture specialist

BidEnergy’s platform provides enterprises with multiple sites control over their energy spend, from sourcing to billing and accounts payable. The acquisition delivers BidEnergy a functioning channel and immediate and direct access to energy category managers in over 100 multisite prospects. RealWinWin secures rebates from utilities on behalf of customers via energy efficiency programs. Acting as an agent, RealWinWin delivers a data service that is highly complementary to BidEnergy’s integrated source-to-pay platform in serving customers with large geographic footprints.
Upvote Downvote

BidEnergy Ltd enters lucrative U.S. energy management market

BidEnergy Ltd (ASX:BID) has formally launched its cloud-based source-to-pay energy management platform in the U.S. market. BidEnergy’s platform provides enterprises with multiple sites control over their energy spend, from sourcing to billing and accounts payable. As a “source to pay” solution, the platform uses automation to deliver value over the entire contract lifecycle, with savings from advanced sourcing and analytics to reduce utility charges.
Upvote Downvote

Intermin, Primary in gold deals

Two Western Australian gold hopefuls, Intermin Resources and Primary Gold, have announced earn-in and drilling-for-equity deals, respectively, to progress potential gold projects.
Upvote Downvote

BidEnergy Ltd clinches deal with BP plc for Australia and New Zealand

Newly listed BidEnergy Ltd (ASX:BID) has soared after clinching an agreement to supply its cloud-based energy management platform to BP plc's (LON:BP) Australian and New Zealand businesses for electricity supplies. BidEnergy had just completed a backdoor listing on the ASX earlier this week through Cove Resources Ltd after raising $7 million in new capital. BidEnergy’s platform provides enterprises with multiple sites control over their energy spend, from sourcing to billing and accounts payable.
Upvote Downvote

BidEnergy, Syntonic start trading

Shareholders in one-time mining companies Cove Resources and Pacific Ore have enjoyed solid gains after the two companies resumed trading on the ASX as tech plays, with one chaired by former Alinta boss Bob Browning and the other run from Seattle.
Upvote Downvote

Disclosure Document

Upvote Downvote

Cove Resources Ltd upbeat on progress of cloud energy management acquisition

Cove Resources Ltd’s (ASX:CVE) transition from the resources sector has gained impetus with the reverse takeover of BidEnergy Pty Ltd and announcement it will provide its cloud-based energy spend management software to a $3 billion ASX-listed support services provider. BidEnergy provides energy spend management platforms that enable users to manage their energy spend life cycle from sourcing, category management through finance and account payable.
Upvote Downvote


Related Articles

GNCA: Genocea Biosciences Analysis and Research Report

2018-04-25 - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN:, Inc Analysis and Research Report

2018-04-25 - Asif

Overview opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...